- Physics-based plus ML molecular simulation
- Built specifically for drug discovery teams, not bolt-on AI
- Scales to organization-wide healthcare rollouts
Schrödinger
Physics-based and ML molecular simulation
SF8
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Support protein engineering programsPharma, biotech, and materials teams
Support protein engineering programsPharma, biotech, and materials teams
Best for
Pharma, biotech, and materials teams
Pricing
Custom
SoftFinders Score
8 / 10
Overview
What is Schrödinger?
Schrödinger is a computational platform company offering physics-based and machine learning software for molecular design and discovery. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.
Schrödinger is aimed at pharma, biotech, and materials teams, and its main draw is physics-based plus ML molecular simulation. The main caveat to weigh: platform depth requires skilled users. Pricing is sales-led and scoped per buyer rather than posted publicly. Confirm scope, integration plan, and clinical review process before adoption.
KEY FEATURES
What you get out of the box
Lab Integration
Connects discovery insights with wet-lab workflows
Partner Workflows
Workflows for pharma partner collaborations
Target Discovery
Identifies potential drug targets from biological data
Molecule Design
Generates and ranks small molecule candidates
Protein Modeling
Predicts and designs protein structures
Knowledge Graph
Connects biological and chemical knowledge sources
USE CASES
Where teams put it to work
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Editorial Take
What we like, and what to verify
- Platform depth requires skilled users
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
FAQ